Theresa Beach

• Responsible for driving the commercial strategy of Petosemtamab from Phase 1 to Four Phase 3 studies (2 in process) along with multiple LCM Phase 2 trials. Merus company valuation based on the performance and positioning of this asset. Leading to buyout by Genmab for $8B based on HNSCC success alone. • Developed high-priority, high-impact projects across the organization, through partnering with scientific and business leaders to drive corporate strategy, business model innovation, pipeline strategy, market analysis, investor relations, and business development. • Led the commercialization and strategic planning activities for bispecific antibodies (bAb) & Antibody-drug-conjugates (ADC) R&D assets in oncology & immunology, including indication prioritization, target product profile development, scientific platform, and commercialization plans, based on comprehensive understanding of market dynamics. • Developed multiple financial valuation models for asset development and LCM analysis which supported strategic development, partnership efforts and corporate valuation. Leading to successful partnership with Biohaven, corporate spin out of “OneFourBio” and the corporate buyout by Genmab. • Successfully translate vision and strategy into executable plans with identified resources and timelines. • Partner with internal stakeholders, such as the marketing, scientific, communications and business development teams, to ensure alignment and consistency in messaging and branding.

• Global commercial lead for cross-functional program teams for oncology and immuno-oncology new products development. This includes novel next-generation immune checkpoints, immuno-modulators, and various targeted therapies across solid tumors and hematology. • Directed commercialization and strategic planning activities for early R&D assets, achieving milestones in indication prioritization, target product profile development, scientific platform, and commercialization plans, based on comprehensive understanding of market dynamics and trends. • Led the development of business case market assessments, primary and secondary research to gain a clear understanding of opportunities to ensure the development of innovative, differentiated, and targeted products for unmet needs in oncology, including planning for life cycle management.

• Implemented new commercial department to lead the pipeline strategy and launch planning for the company’s first clinical assets Olutasidenib into AML 2021 & glioma 2022, and Etavopivat in sickle cell disease (SCD) 2024. Built out full commercial functionality via an external network. • Commercial lead for cross-functional program teams for five clinical assets in oncology, SCD and NASH, ensuring innovation, market knowledge, strategic insight was incorporated into product development. • Led core team of investor relations, public relations, and medical communications agencies in development of FORMA’s external market messaging and vision. This team developed the new company website, investor presentations, due diligence data room, publications plan, scientific platforms, KOL profile maps, advisory board presentations, and conference strategies. • Developed, led, and executed a robust, integrated vision and strategy for the overall portfolio, including lifecycle management for all products to support the corporate mission. This included business case analysis for all pipeline assets, including: NPV valuations, primary and secondary market research, pricing, market access, and regulatory analysis. • Expanded pipeline opportunities via disease area strategy, indication prioritization, and white map market analysis for each product and repositioned assets into more commercially favorable indications, increasing the portfolio valuation. • Created commercial launch strategy, tactics, and budget for the AML, glioma and SCD product launches.

• Global commercial lead for cross-functional program teams for 14 different assets (nine oncology and five immuno-oncology). This included novel and many first-in-class DNA damage repair molecules, immune checkpoints, immuno-modulators, and various targeted therapies across solid tumors and hematology. • Led the commercialization and strategic planning activities for early R&D assets, including indication prioritization, target product profile development, scientific platform, and commercialization plan, based on comprehensive understanding of market dynamics and trends. • Led the development of business case market assessments, tumor prioritizations, primary and secondary research to gain a clear understanding of opportunities to ensure the development of innovative, differentiated, and targeted products for unmet needs in oncology, including planning for life cycle management. • Led the development of due diligence, commercial assessments, and forecasts for internal and potential external investment in close collaboration with forecasting and business development teams. • Contributed to the long-term commercial and portfolio management strategy to ensure early R&D activities and business development acquisitions were in line with global franchise positioning. • Developed and executed the first, large-scale pipeline marketing presence at the international ESMO & ASCO conferences for Merck KGaA and EMD Serono.

• Key financial business partner to the oncology and N&I global commercial franchise leadership teams. Provided decision analysis and budget management to business and finance executive management teams. • Partnered with business development to support external deals and collaboration opportunities. Managed multiple valuation assessments and successfully executed the Erbitux co-development Japan deal (valued at $1.3B) in December 2014 between Merck KGaA, BMS, and Eli Lilly.

• Provided executive management for life science companies during start-up and growth phases in the diagnostic, pharmaceutical, nutraceutical, and medical device industries. • Delivered fundraising, business development, and strategy efforts for early-stage companies. Aided with presentations, strategic focus, and connections to venture capital, angel financers, and business grant resources.

• Identified three target investment areas, creating cornerstone companies in medical diagnostic, nutraceutical, and medical device markets, driving strategic growth. • Provided direct support to developing portfolio companies, including business development, product and commercialization development, and clinical trial strategy, enhancing company performance. • Investigated new venture opportunities via due diligence of management team, financials, scientific analysis, and business strength, ensuring informed investment decisions.

• Member of a 6-person executive team responsible for company turnaround, and roll up of four additional companies into a single entity and acquisition by BioMérieux Inc. • Developed and managed two new marketing departments, driving full marketing development, pricing structure and product management thereby increasing PML's revenues by 40%. • Launched multiple new product lines and established an international distribution network, expanding PML's market beyond the US and Canada.

• Competitive roadmap strategic analysis: Financial analysis and strategic insights for pipeline assets.

Project Manager • Executed project management leadership for three cross-functional projects: $30M Ketolide antibacterial program, $5M hepatitis C virus protease program, and $1M GMP chemistry laboratory construction. Antibacterial Drug Discovery Program Leader • Designed, built, and implemented new antibacterial drug discovery program and laboratory.